Clinical trials: Stage IV Breast Cancer AJCC V7
Breast Cancer
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00031876
- Testing
- capecitabine, paclitaxel
- Where
- 2 sites in Switzerland
- Volunteers
- 34 people
- Sponsor
- Swiss Cancer Institute
Male Breast Carcinoma, Recurrent Breast Carcinoma
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
This phase I/II trial is studying the side effects and best dose of cixutumumab when given together with temsirolimus and to see how well they work in treating patients with breast cancer that has recurred (come back) at or near…
- Conditions
- Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT00699491
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 192 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003920
- Testing
- filgrastim, cyclosporine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, Davis
Breast Cancer
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00810797
- Testing
- exemestane, laboratory biomarker analysis, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
This phase II trial studies how well temsirolimus works in treating patients with breast cancer that has spread to other places in the body.
- Conditions
- Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
- Trial name
- NCT00376688
- Testing
- Laboratory Biomarker Analysis, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Breast Cancer, Stage IIIA Breast Cancer
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative…
- Conditions
- Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- InCITe (NCT03971409)
- Testing
- Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib
- Where
- 12 sites in United States
- Volunteers
- 145 people
- Sponsor
- Laura Huppert, MD, BA
Breast Cancer, Lung Cancer
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00005023
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- University of Washington
Breast Cancer
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Naltrexone may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00379197
- Testing
- naltrexone, PET scan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Estrogen Receptor Positive, Male Breast Carcinoma
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
This phase II trial studies how well giving lapatinib ditosylate together with tamoxifen citrate works in treating patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes or to other…
- Conditions
- Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive, Recurrent Breast Carcinoma
- Trial name
- NCT00118157
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tamoxifen Citrate
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of CF33-hNIS-antiPDL1 in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT05081492
- Testing
- Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003902
- Testing
- capecitabine, vinorelbine tartrate
- Where
- Switzerland
- Volunteers
- 110 people
- Sponsor
- Swiss Cancer Institute
Triple -Negative Breast Cancer, Estrogen Receptor Negative
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
This pilot trial studies how well chemokine modulation therapy works when given prior to pembrolizumab in treating participants with triple-negative breast cancer that has spread to other places in the body.
- Conditions
- Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative, Anatomic Stage IV Breast Cancer AJCC
- Trial name
- NCT03599453
- Testing
- Biopsy, Chemokine Modulation Therapy, Celecoxib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of alpelisib when given together with enzalutamide in treating patients with androgen receptor and PTEN positive breast cancer that has spread to other places in the body.
- Conditions
- Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT03207529
- Testing
- Alpelisib, Enzalutamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Breast Cancer, Stage IV Breast Cancer
Cabergoline in Metastatic Breast Cancer
Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that elevated levels of the hormone prolactin might be associated with an increased risk of breast cancer.
- Trial name
- NCT01730729
- Testing
- cabergoline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Recurrent Breast Carcinoma, Stage IV Breast Cancer
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
This phase II trial studies how well eribulin mesylate works in treating patients with previously treated breast cancer that has spread to other places in the body.
- Trial name
- NCT01908101
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis
- Where
- 12 sites in United States
- Volunteers
- 86 people
- Sponsor
- University of Washington
Breast Cancer
Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations
RATIONALE: Genetic counseling and using an interactive computer program may help women at risk for breast cancer make medical decisions about treatment.
- Trial name
- NCT00416754
- Testing
- counseling intervention
- Volunteers
- 1,109 people
- Sponsor
- Georgetown University
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers
RATIONALE: Vaccines made from gene-modified tumor cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop tumor cells from…
- Trial name
- NCT00095862
- Testing
- allogeneic GM-CSF-secreting breast cancer vaccine, recombinant interferon alfa, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Wiseman Research Initiatives LLC
Breast Cancer
Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00943410
- Testing
- external beam radiation therapy, Herceptin
- Volunteers
- 19 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Central Nervous System Metastases, Male Breast Cancer
A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
This pilot clinical trial studies irinotecan hydrochloride in treating patients with breast cancer and brain metastases that progressed after whole brain radiation therapy or stereotactic radiosurgery.
- Conditions
- Central Nervous System Metastases, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01939483
- Testing
- irinotecan hydrochloride, laboratory biomarker analysis
- Sponsor
- University of California, Irvine